PainChek’s UK Surge Highlights Rising Pressure on Aged Care Pain Management
PainChek has reported a strong quarter in the UK aged care sector, securing 4,000 new licenses and driving 9% quarter-on-quarter growth, signalling rising demand for its AI-driven pain assessment technology.
- 4,000 new contracted licenses in UK aged care market
- 9% quarter-on-quarter revenue growth adding AUD 230,000 ARR
- PainChek recognised as priority solution over falls detection tech
- Ongoing progress in North America and infant pain assessment product
- Upcoming quarterly update to reveal total UK licenses and ARR
Strong Momentum in UK Aged Care
PainChek Limited, the Australian developer of the world’s first AI-powered pain assessment app, has announced significant sales momentum in the UK aged care market. The company secured 4,000 new contracted licenses this quarter, translating to a 9% increase in quarterly revenue and an additional AUD 230,000 in annual recurring revenue once fully implemented. This growth underscores the increasing adoption of digital health solutions in aged care, particularly those that improve clinical outcomes and operational efficiency.
Why Pain Assessment Is Taking Priority
Unlike other technologies such as falls detection, PainChek’s AI-driven tool is gaining recognition as a priority within aged care facilities. Providers are placing greater emphasis on effective pain management, a critical factor in enhancing resident care quality and meeting stringent regulatory requirements. Facilities using PainChek report improved pain identification and management, which not only benefits residents but also streamlines care delivery and documentation.
Global Expansion and Product Innovation
Beyond the UK, PainChek is advancing its footprint in North America, where early commercial and strategic initiatives are underway. The company is also progressing with its PainChek Infant product, designed to assess pain in infants aged one to twelve months using facial recognition technology. These developments highlight PainChek’s ambition to broaden its impact across different demographics and geographies.
Looking Ahead
The company’s CEO, Philip Daffas, emphasised PainChek’s strong positioning to capitalise on the growing global demand for digital health solutions in aged care. With major market opportunities still ahead, particularly in North America and other verticals, PainChek is poised for continued growth. Investors and industry watchers will be keenly awaiting the upcoming quarterly business update for a fuller picture of total UK licenses and revenue.
Bottom Line?
PainChek’s UK growth momentum and expanding global initiatives set the stage for a pivotal year ahead in digital aged care solutions.
Questions in the middle?
- What are the total UK licenses and ARR figures expected in the next quarterly update?
- How will PainChek’s North American commercial initiatives translate into revenue growth?
- When will the PainChek Infant product be commercially available and what is its market potential?
